Thermo Fisher Scientific to buy Olink in $3.1 billion deal

The deal lifted Olink's U.S.-listed shares nearly 67 per cent in early trading, while shares of Thermo Fisher were down over 1 per cent. Thermo Fisher has been struggling with softening demand for its life sciences offerings, which includes discovery and production of new drugs and vaccines, as its biotech clients face a funding crunch.

from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/f6bJdmu
via